A Clinical Trial of PEGIFNα1b in Chinese Healthy Adults
Status:
Completed
Trial end date:
2020-10-22
Target enrollment:
Participant gender:
Summary
This is a Phase I，randomized, double-blind, placebo controlled,dose escalated,single
administrated clinical trial in Chinese healthy adult's volunteers.
In the trial, it is planned to enroll 50 subjects, randomized to 5 dosage groups to receive
the test drug and the placebo control.